Duration of ischemia and treatment effects of pre‐ versus in‐hospital ticagrelor in patients with ST‐segment elevation myocardial infarction: Insights from the ATLANTIC study

[1]  E. Vicaut,et al.  Effect of Pre-Hospital Ticagrelor During the First 24 h After Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction: The ATLANTIC-H²⁴ Analysis. , 2015, JACC. Cardiovascular interventions.

[2]  G. Montalescot,et al.  P2Y12 receptor inhibition and effect of morphine in patients undergoing primary PCI for ST-segment elevation myocardial infarction , 2015, Thrombosis and Haemostasis.

[3]  G. Montalescot,et al.  Prehospital ticagrelor in ST-segment elevation myocardial infarction. , 2014, The New England journal of medicine.

[4]  W. Cantor,et al.  Ambulance or in-catheterization laboratory administration of ticagrelor for primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: rationale and design of the randomized, double-blind Administration of Ticagrelor in the cath Lab or in the Ambulance for New ST elev , 2013, American heart journal.

[5]  G. Montalescot,et al.  Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. , 2012, JAMA.

[6]  Ankit Garg,et al.  Predictors of early, late, and very late stent thrombosis after primary percutaneous coronary intervention with bare-metal and drug-eluting stents for ST-segment elevation myocardial infarction. , 2012, JACC. Cardiovascular interventions.

[7]  K. Huber,et al.  Efficacy and safety of a high loading dose of clopidogrel administered prehospitally to improve primary percutaneous coronary intervention in acute myocardial infarction: the randomized CIPAMI trial , 2012, Clinical Research in Cardiology.

[8]  M. Shishehbor.  Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction , 2011 .

[9]  J. Weisel,et al.  Composition of coronary thrombus in acute myocardial infarction. , 2011, Journal of the American College of Cardiology.

[10]  P. Stella,et al.  The golden hour of prehospital reperfusion with triple antiplatelet therapy: a sub-analysis from the Ongoing Tirofiban in Myocardial Evaluation 2 (On-TIME 2) trial early initiation of triple antiplatelet therapy. , 2010, American heart journal.

[11]  P. Armstrong,et al.  Use of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention: insights from the APEX-AMI trial. , 2010, European heart journal.

[12]  B. Gersh.  Impact of Primary Coronary Angioplasty Delay on Myocardial Salvage, Infarct Size, and Microvascular Damage in Patients With ST-Segment Elevation Myocardial Infarction: Insight From Cardiovascular Magnetic Resonance , 2010 .

[13]  E. Topol,et al.  Benefit of facilitated percutaneous coronary intervention in high-risk ST-segment elevation myocardial infarction patients presenting to nonpercutaneous coronary intervention hospitals. , 2009, JACC. Cardiovascular interventions.

[14]  Harlan M Krumholz,et al.  Association of door-to-balloon time and mortality in patients admitted to hospital with ST elevation myocardial infarction: national cohort study , 2009, BMJ : British Medical Journal.

[15]  A. Skene,et al.  Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. , 2009, American heart journal.

[16]  J. Ottervanger,et al.  Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial , 2008, The Lancet.

[17]  N. Ozdemir,et al.  Clinical and procedural predictors of no-reflow phenomenon after primary percutaneous coronary interventions: experience at a single center. , 2008, Circulation journal : official journal of the Japanese Circulation Society.

[18]  R. Gibbons,et al.  Impact of time to treatment on myocardial reperfusion and infarct size with primary percutaneous coronary intervention for acute myocardial infarction (from the EMERALD Trial). , 2007, The American journal of cardiology.

[19]  J. Ottervanger,et al.  Combination of electrocardiographic and angiographic markers of reperfusion in the prediction of infarct size in patients with ST-segment elevation myocardial infarction undergoing successful primary angioplasty. , 2007, International journal of cardiology.

[20]  Harlan M Krumholz,et al.  Effect of door-to-balloon time on mortality in patients with ST-segment elevation myocardial infarction. , 2006, Journal of the American College of Cardiology.

[21]  J. Weisel,et al.  Images in cardiovascular medicine. Architecture of intracoronary thrombi in ST-elevation acute myocardial infarction: time makes the difference. , 2006, Circulation.

[22]  Gregg W Stone,et al.  Pharmacological facilitation of primary percutaneous coronary intervention for acute myocardial infarction: is the slope of the curve the shape of the future? , 2005, JAMA.

[23]  Elliott M. Antman,et al.  Time Delay to Treatment and Mortality in Primary Angioplasty for Acute Myocardial Infarction: Every Minute of Delay Counts , 2004, Circulation.

[24]  S. de Servi,et al.  Integrated Analysis of Myocardial Blush and ST-Segment Elevation Recovery After Successful Primary Angioplasty: Real-Time Grading of Microvascular Reperfusion and Prediction of Early and Late Recovery of Left Ventricular Function , 2002, Circulation.

[25]  R. Gibbons,et al.  TIMI Myocardial Perfusion Grade and ST Segment Resolution: Association With Infarct Size as Assessed by Single Photon Emission Computed Tomography Imaging , 2002, Circulation.

[26]  Eric Boersma,et al.  Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour , 1996, The Lancet.

[27]  Sarah Parish,et al.  Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. , 1988, Journal of the American College of Cardiology.